Pacira BioSciences Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Pacira Pharma (PCRX) Misses Q1 EPS by 19c
May 4, 2022 8:07 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.64, $0.19 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $158 million versus the consensus estimate of $159.34 million.
Financial Guidance:
The companys product sales continue to be impacted by COVID-19, which has caused... More
